Source: Cancer Immunology Immunotherapy. Unidades: FOB, FMRP
Subjects: CARCINOMA DE CÉLULAS ESCAMOSAS (IMUNOLOGIA), NEOPLASIAS BUCAIS (IMUNOLOGIA), LÁBIO, INFLAMAÇÃO
ABNT
MALASPINA , Tatiana Salles de Souza et al. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunology Immunotherapy, v. 60, n. 7, p. 965-974, 2011Tradução . . Disponível em: https://doi.org/10.1007/s00262-011-1007-5. Acesso em: 28 ago. 2024.APA
Malaspina , T. S. de S., Gasparoto, T. H., Costa, M. R. S. N., Melo Jr, E. J. F. de, Ikoma, M. R. V., Damante, J. H., et al. (2011). Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunology Immunotherapy, 60( 7), 965-974. doi:10.1007/s00262-011-1007-5NLM
Malaspina TS de S, Gasparoto TH, Costa MRSN, Melo Jr EJF de, Ikoma MRV, Damante JH, Cavassani KA, Garlet GP, Silva JS da, Campanelli AP. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma [Internet]. Cancer Immunology Immunotherapy. 2011 ; 60( 7): 965-974.[citado 2024 ago. 28 ] Available from: https://doi.org/10.1007/s00262-011-1007-5Vancouver
Malaspina TS de S, Gasparoto TH, Costa MRSN, Melo Jr EJF de, Ikoma MRV, Damante JH, Cavassani KA, Garlet GP, Silva JS da, Campanelli AP. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma [Internet]. Cancer Immunology Immunotherapy. 2011 ; 60( 7): 965-974.[citado 2024 ago. 28 ] Available from: https://doi.org/10.1007/s00262-011-1007-5